Neonatal screening for congenital toxoplasmosis in a cohort of 165 women infected during pregnancy and influence of in utero treatment on the results of neonatal tests.
The aim of this study was to determine the performances of methods used for the neonatal diagnosis of congenital toxoplasmosis. We included 165 pregnant women infected during pregnancy over a 10-year period. Fifty-seven cases of congenital toxoplasmosis were demonstrated (34.5%). Neonatal diagnosis gave positive results in 50 cases (88%). Parasites were isolated from placenta or cord blood in 61% of the infected newborns, more frequently from placenta (60%) than from cord blood (43%). This method was the only criterion of infection in 18% of these infected infants. The detection of specific IgM and IgA antibodies performed on 42 sera of infected infants allowed the diagnosis of congenital infection in 34 cases (81%). IgA antibodies were more frequently detected (60%) than specific IgM (50%). Neonatal and prenatal screening were carried out for 143 pregnant women. This combination diagnosed 39 of 40 infected infants (98%). Prenatal diagnosis identified 30 of 40 cases (75%). Nine cases were diagnosed through neonatal screening and one case with the postnatal follow-up. When prenatal diagnosis was positive, pyrimethamine and sulfadoxine were administered to the mothers (25 cases) in addition to spiramycin. Toxoplasma gondii was less frequently isolated in the placenta and the cord blood of these women (32% and 19%, respectively) than in women treated by spiramycin alone (83% and 63%) proving the antiparasitic action of these drugs. In conclusion, neonatal screening combining parasite detection in placenta and immunological methods on cord blood is essential particularly when prenatal diagnosis is negative. Therefore, when this diagnosis is positive, a treatment with pyrimethamine and sulfamide can be started in the first month of life.
Bessières
M H
MH
Department of Parasitology, CHU, Rangueil 1 Avenue du Professeur Jean Poulhès, 31403 Cedex 4, Toulouse, France. bessieres.m@chu-toulouse.fr
Berrebi
A
A
Rolland
M
M
Bloom
M C
MC
Roques
C
C
Cassaing
S
S
Courjault
C
C
Séguéla
J P
JP
D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000627:therapeutic use; D015331:Cohort Studies; D005260:Female; D005312:Fetal Blood / Q000469:parasitology; D005315:Fetal Diseases / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D007231:Infant, Newborn; D015997:Neonatal Screening; D010920:Placenta / Q000469:parasitology; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000469:parasitology*; D011296:Prenatal Diagnosis; D011739:Pyrimethamine / Q000008:administration & dosage / Q000627:therapeutic use; D015572:Spiramycin / Q000008:administration & dosage / Q000627:therapeutic use; D013413:Sulfadoxine / Q000008:administration & dosage / Q000627:therapeutic use; D014122:Toxoplasma / Q000276:immunology / Q000302:isolation & purification; D014125:Toxoplasmosis, Congenital / Q000175:diagnosis* / Q000188:drug therapy*
D000913:Antibodies, Protozoan; D000981:Antiprotozoal Agents; D007070:Immunoglobulin A; D007075:Immunoglobulin M; D015572:Spiramycin; D013413:Sulfadoxine; D011739:Pyrimethamine